Acute kidney injury in cirrhosis

Hepatology

Volumn 48, Issue 6, 2008, Pages 2064-2077

  Garcia Tsao, Guadalupe ^a   Parikh, Chirag R ^a,c   Viola, Antonella ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; CREATININE; MIDODRINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; PLACEBO; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ABDOMINAL CRAMP; ACUTE KIDNEY FAILURE; ACUTE KIDNEY INJURY; ALBUMIN DIALYSIS; BACTERIAL INFECTION; BRADYCARDIA; BRONCHOSPASM; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSPNEA; GASTRIC DYSMOTILITY; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE EXTRASYSTOLE; HEPATORENAL SYNDROME; HUMAN; HYPERTENSION; HYPOKINESIA; HYPOVOLEMIA; INTESTINAL BLEEDING; INTESTINE ISCHEMIA; KIDNEY BLOOD FLOW; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG EDEMA; MAINTENANCE DRUG DOSE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PERITONITIS; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY ACIDOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN TINGLING; SODIUM RETENTION; SURVIVAL RATE; TACHYCARDIA; THORAX PAIN; TONGUE DISEASE; TONGUE ISCHEMIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT RESPONSE; UREMIA; URINE VOLUME; VASOCONSTRICTION; VASODILATATION; VOMITING; WEIRD SENSATION; RENAL REPLACEMENT THERAPY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY FAILURE, ACUTE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RENAL DIALYSIS; VASOCONSTRICTOR AGENTS;

EID: 58149384525     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22605     Document Type: Review

References (86)

1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
2. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
3. Weismuller TJ, Prokein J, Becker T, Barg-Hock H, Klempnauer J, Manns MP, et al. Prediction of survival after liver transplantation by pre-transplant parameters. Scand J Gastroenterol 2008;43:736-746.
4. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008;28:81-95.
5. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008;48(Suppl 1):S93-S103.
6. Munoz SJ. The hepatorenal syndrome. Med Clin NorthAm2008;92:813-837.
7. Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:111-123.
8. Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol 2007;13:5552-5559.
9. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
10. Epstein M, Berk DP, Hollenberg NK, Adams DF, Chalmers TC, Abrams HL, et al. Renal failure in the patient with cirrhosis: the role of active vasoconstriction. Am J Med 1970;49:175-185.
11. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988;8:1151-1157.
12. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. HEPATOLOGY 2006;43:S121-S131.
13. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
14. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. HEPATOLOGY 2005;42:439-447.
15. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. HEPATOLOGY 2005;41:1282-1289.
16. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. HEPATOLOGY 1996;23:164-176.
17. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the international ascites club. Gut 2007;56:1310-1318.
18. Hampel H, Bynum GD, Zamora E, El-Serag HB. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001;96:2206-2210.
19. Peron JM, Bureau C, Gonzalez L, Garcia-Ricard F, de Soyres O, Dupuis E, et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol 2005;100: 2702-2707.
20. Terra C, Guevara M, Torre A, Gilabert R, Fernandez J, Martin-Llahi M, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129:1944-1953.
21. du Cheyron D, Bouchet B, Parienti JJ, Ramakers M, Charbonneau P. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med 2005;31:1693-1699.
22. Wu CC, Yeung LK, Tsai WS, Tseng CF, Chu P, Huang TY, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol 2006;65:28-33.
23. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type I heparorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-930.
24. Fang JT, Tsai MH, Tian YC, Jenq CC, Lin CY, Chen YC, et al. Outcome predictors and new score of critically ill cirrhotic patients with acute renal failure. Nephrol Dial Transplant 2008;23:1961-1969.
25. McGuire BM, Julian BA, Bynon JS Jr, Cook WJ, King SJ, Curtis JJ, et al. Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006;144:735-741.
26. Garcia-Tsao G. Further evidence against the use of aminoglycosides in cirrhotic patients. Gastroenterology 1998;114:612-613.
27. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953;32:1025-1033.
28. Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 1977; 37:635-642.
29. Cohn JN. Renal hemodynamic alterations in liver disease. Perspect Nephrol Hypertens 1976;3:255-234.
30. Stadlbauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008;134:111-119.
31. Mandal AK, Lansing M, Fahmy A. Acute tubular necrosis in hepatorenal syndrome: an electron microscopy study. Am J Kidney Dis 1982;2:363-374.
32. Rector WG, Jr., Kanel GC, Rakela J, Reynolds TB. Tubular dysfunction in the deeply jaundiced patient with hepatorenal syndrome. HEPATOLOGY 1985;5:321-326.
33. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. HEPATOLOGY 1999;29:1690-1697.
34. Star RA. Treatment of acute renal failure. Kidney Int 1998;54:1817-1831.
35. Tomlanovich S, Golbetz H, Perlroth M, Stinson E, Myers BD. Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis 1986;8:332-337.
36. Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA. Molecular and structural consequences of early renal allograft injury. Kidney Int 2002;61:686-696.
37. Dimeski G, McWhinney B, Jones B, Mason R, Carter A. Extent of bilirubin interference with Beckman creatinine methods. Ann Clin Biochem 2008;45:91-92.
38. Cholongitas E, Shusang V, Marelli L, Nair D, Thomas M, Patch D, et al. Review article: renal function assessment in cirrhosis-difficulties and alternative measurements. Aliment Pharmacol Ther 2007;26:969-978.
39. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine. HEPATOLOGY 1999;30:870-875.
40. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type I hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001;64:15-19.
41. Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barriere E, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002;17:882-888.
42. Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, DiMartino V, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153-158.
43. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin J-L, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. HEPATOLOGY 2002;36:374-380.
44. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-156.
45. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005;20: 1813-1820.
46. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008;53:830-835.
47. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134:1360-1368.
48. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134: 1352-1359.
49. Dudley FJ, Kanel GC, Wood LJ, Reynolds TB. Hepatorenal syndrome without avid sodium retention. HEPATOLOGY 1986;6:248-251.
50. Diamond JR, Yoburn DC. Nonoliguric acute renal failure associated with a low fractional excretion of sodium. Ann Intern Med 1982;96:597-600.
51. Eknoyan G. Letter: renal disorders in hepatic failure. Br Med J 1974;2: 670.
52. Elsom KA. Renal function in obstructive jaundice. Arch Intern Med 1937; 60:1028-1033.
53. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004;43:405-414.
54. Krag A, Moller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. HEPATOLOGY 2007;46: 1863-1871.
55. Rimola A, Gavaler JS, Schade RR, el Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology 1987;93:148-156.
56. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995;59:361-365.
57. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. HEPATOLOGY 2002;35:1179-1185.
58. Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006;6:2651-2659.
59. Davis CL. Impact of pretransplant renal failure: when is listing for kidneyliver indicated? Liver Transpl 2005;11:S35-S44.
60. Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004;40: 140-146.
61. Davis CL, Feng S, Sung R, Wong F, Goodrich NP, Melton LB, et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007;7:1702-1709.
62. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004;10: 301-309.
63. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. HEPATOLOGY 2002;36:941-948.
64. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2001;33:43-48.
65. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. HEPATOLOGY 2004;40:55-64.
66. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/ Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52: 742-748.
67. Pomier-Layrargues G, Paquin SC, Hassoun Z, LaFortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. HEPATOLOGY 2003;38: 238-243.
68. Wiest R, Tsai M-H, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology 2000;120:975-983.
69. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. HEPATOLOGY 1998; 27:35-41.
70. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-570.
71. Lim JK, Groszmann RJ. Vasoconstrictor therapy for the hepatorenal syndrome. Gastroenterology 2008;134:1608-1611.
72. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007;47:499-505.
73. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103:1689-1697.
74. Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. HEPATOLOGY 1998;28: 416-422.
75. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long-term outcome after transjugular intrahepatic portosystemic stentshunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-295.
76. Michl P, Gulberg V, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: effects in patients with organic or functional renal failure. Scand J Gastroenterol 2000;35:654-658.
77. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective randomized, controlled clinical trial. Liver Transpl 2000;6:277-286.
78. Sanyal AJ, Boyer TD, Teuber PF. Prognostic factors for hepatorenal syndrome (HRS) reversal in patients with type 1 hrs enrolled in a randomized, double-blind,placebo-controlled trial [Abstract]. HEPATOLOGY 2007; 46(Suppl 1):564A.
79. Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-1501.
80. Ruiz del Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113: 579-586.
81. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, et al. Randomized trial comparing albumin, dextran-70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-1010.
82. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.
83. Terg R, Gadano A, Lucero R, Cartier MG, Casciato P, Romero G, et al. Serum creatinine and bilirubin levels at admission are useful to select patients with SBP who should be treated with plasma expansion with albumin [Abstract]. HEPATOLOGY 2006;44(Suppl 1):441A.
84. Casas M, Soriano G, Ayala E, Guarner-Argente C, Ordas I, Merce J, et al. Intravenous albumin is not necessary in cirrhotic patients with spontaneous bacterial peritonitis and low-risk of mortality [Abstract]. J Hepatol 2007;46(Suppl 1):S91A.
85. Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133:818-824.
86. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008;28:26-42.